Read the Peer-Reviewed Science Backing Our Treatment

In this seminal publication, it was discovered and demonstrated that Dendritic Cells possess a never-before-seen intrinsic mechanism critical to appropriate immunity. This mechanism essentially allows for the Dendritic Cell to "sense" the internal and external cellular environments simultaneously to determine if a Th1 Killer T cell response is appropriate and necessary (the type of immune response needed to eliminate viruses and cancers).

This phenomenon is demonstrated down to the MHC binding peptide level and is validated by a variety of measures including decreased CTLA-4 expression, increased CD83 levels, and increased IL-12 and Interferon-𝛾 secretion by the Dendritic Cells and responding T cells, respectively.

Taken together, it is apparent the Dendritic Cells possess a very detailed and important mechanism never previously identified and potentially critical to optimal immune responsiveness.

In this key work which expounds upon numerous publications, including Decker et al (2009), it is shown that this unique and powerful intrinsic Dendritic Cell mechanism is regulated down the level of the specific amino acid sequences being bound to both MHC Class I and II, that they must be bound to MHC Class I and II simultaneously, and that the sequences must match entirely to generate this powerful Th1 immune response.

A change of even a couple of amino acids to eliminate the '100% overlap' completely eliminates the response, demonstrating how fine-tuned and important this biological feat is. Unique to this 'overlapped' mechanism of Dendritic Cell loading is the downstream secretion of a powerful Th1 immune promoter, AIMp1 (a.k.a. p43) and the statistically significant upregulation of antigen-specific Killer T cells in circulation.

These results are repeatedly and eloquently shown through various experiments within this publication, and importantly it is also shown that other stimuli often used with Dendritic Cell or immunotherapy attempts (e.g., TLR agonists, bacterial components, viral components, interferons) were unable to replicate these responses, even when combined.

Taken together, the findings published here are the detailed underpinnings of the mechanism driving the unique and powerful Dendritic Cell technology employed by Giostar.

This work continues to build exponentially on previous published works by showing the importance of 'overlapped' loading in Dendritic Cells in a variety of new systems and targets. Continued study has revealed that the Dendritic Cells are able to immune-attack a wide range of targets if loaded in this way, regardless of where or what the target may be.

It is shown here that this type of immunotherapy (a.k.a. Dendritic Cell 'overlapped' loading with a target) can combine effectively with standard of care cancer treatments (e.g., chemotherapy), that the results are target-specific, and that the combination leads to significantly better treatment outcomes.

Importantly, it is thoroughly demonstrated that a truly unique population of memory T cells are propagated from this type (and only this type) of Dendritic Cell therapy, and that this greatly reduces the risk of relapse and carries significant long-term protection capabilities.

Taken together, it has been shown that this powerful, specific, and special Th1 immune response has numerous unique outcome measures, is able to be translated from laboratory findings to preclinical successes in even very difficult to treat cancer models, and may in fact have strong utility in the future global treatment approach for cancer.

This is an early analysis of the APCEDEN clinical trial referenced above, in which potency assays were measured for Interferon-𝛾 release, expression of various markers including CD83 and CD40, CD8 / CD4 ratios, and how various patients were progressing at that time.

This is a case report of a patient treated with Th1-empowered Dendritic Cells, in which remission was observed. As of 2022, this patient is still alive.

Unique to this 'overlapped' mechanism of Dendritic Cell loading is the downstream secretion of a powerful Th1 immune promoter, AIMp1 (a.k.a. p43) and the statistically significant upregulation of antigen-specific Killer T cells in circulation.

Taken together, the findings published here are the detailed underpinnings of the mechanism driving the unique and powerful Dendritic Cell technology employed by Giostar.

This is a case report of a patient treated with Th1-empowered Dendritic Cells, in which remission was observed. As of 2022, this patient is still alive.

It is shown here that this type of immunotherapy can combine effectively with standard of care cancer treatments (e.g., chemotherapy), that the results are target-specific, and that the combination leads to significantly better treatment outcomes.

Taken together, it has been shown that this powerful, specific, and special Th1 immune response has numerous unique outcome measures and may in fact have strong utility in the future global treatment approach for cancer.

This canine trial was focused on extrapolating the results of the powerful Th1-empowered Giostar Dendritic Cells from the lab to the clinic in real-world cases and attempted to overcome the most aggressive cancer simply known to exist – canine splenic hemangiosarcoma (median survival of 48 days, 100% lethal).

Though not every dog was "cured," 40% showed significant improvement including an example of long-term remission with no cancer identified at time of autopsy (death due to old age). These results provide preliminary evidence of the utility of this science in real cases, and suggests further study and use is extremely warranted.

Code named APCEDEN in India, the treatment showed statistically significant improvement in survival, with limited adverse events, and ultimately received regulatory approval as a treatment within India for certain cancers.

Taken together, these results demonstrated conclusively the importance of Giostar's Th1-empowered Dendritic Cells in the ability to engender an anti-cancer immune response.

This publication is one of the earliest portrayals of the ability of Dendritic Cells to recognize internal and external antigens at the same time and respond more powerfully than if they are exposed to only internal or external antigens.

This publication exhaustively demonstrates that Dendritic Cells possess the immune suppressor CTLA-4 and normally secrete this molecule to reduce inflammation.

In a variety of publications presented here, it is shown that Th1 'overlapped' Dendritic Cells reduce their CTLA-4 expression and secretion and this leads to stronger anti-cancer immune responses. This publication was highlighted on the cover of the journal.

This publication demonstrates the critical role of AIMp1 (also known as p43) in potentiating Th1 immune polarization. The findings confirm that the downstream secretion of AIMp1 from properly loaded Dendritic Cells is not incidental but rather essential to generating a robust anti-tumor immune response.

The research validates key mechanistic elements that underpin the Giostar treatment protocol and supports the broader body of work demonstrating the superiority of the double-loaded Dendritic Cell approach.